Podcasts about loscalzo

This week, the Social Media Editors of Circulation interview the recipients for the 2023 Loscalzo and Willerson Awards. Please join Maryjane Farr, Susmita Sahoo, Shirin Doroudgar, Pishoy Gouda and Peter Kennel as they talk with authors Zihan Ma, Chenfeng Mao, and Alexander Sandhu. For the episode transcript, visit:  https://www.ahajournals.org/do/10.1161/podcast.20231222.991468

Welcome to a special episode with Dr. Rita Marie Loscalzo, a metabolic recovery specialist and the founder of the Institute for Nutritional Endocrinology. In this enlightening session, we dive into the future of empowered healthcare, heart health, and the mission to help people take control of their well-being.   Highlights:   Introduction to Dr. Rita Marie Loscalzo, her extensive background, and the focus on empowered healthcare. The journey that led Dr. Rita Marie to the field of metabolic recovery and her determination to prevent sudden cardiovascular events. Details about the upcoming Shine event, focusing on cardiovascular health, for healthcare practitioners and those aspiring to make a difference. The dates of the Shine event, October 27th-29th, and its online format. The importance of the event and reaching those who want to be proactive in their health. Dr. Rita Marie highlights the need for individuals to seek answers and not rely solely on conventional medicine. A discussion on Dr. Rita Marie's journey and the significance of her work for individuals, families, and healthcare practitioners. An emphasis on the connection between hidden trauma and cardiovascular disease, shedding light on its importance.   Websites mentioned: https://inemethod.com/    Institute for Nutritional Endocrinology - Find a practitioner near you. Join Dr. Rita Marie Loscalzo at the Shine event for a transformative dive into cardiovascular health. Don't wait for a diagnosis to take control of your well-being—embrace empowered healthcare. https://doctorritamarie.isrefer.com/go/SHINE/DrIreneCop/    If you enjoyed this episode, please rate, follow, and review our podcast. Your support keeps us going!   -- Listen, rate, and subscribe! Let's get your success and life back on track...Connect with Dr. Irene and the Faculty of the Success S.H.I.F.T. Institute:   See if it's a fit to transform your life with the Success S.H.I.F.T.  Institute: https://drirene.life/strategycall      You deserve it and I will get you there. Trust the process!   CONNECT WITH ME ON SOCIAL MEDIA:   If you haven't already done so: Join our exclusive private Community The Success S.H.I.F.T., for a Community of Support and Learning in your success and life journey: https://drirene.life/freecommunity    Follow me on LinkedIn: https://www.linkedin.com/in/drirenecop/   Like me on Facebook: Dr. Irene   Subscribe on Youtube: The Success S.H.I.F.T. with Dr. Irene    Follow me on Instagram: @dr.irenec    Look us up on our website: https://successshiftinstitute.com  SUBSCRIBE: iTunes: https://podcasts.apple.com/us/podcast/self-heal-with-dr-irene/id1561226627 Spotify: https://open.spotify.com/show/1pxldTJY5MZmneyz8IpSvm Youtube: https://www.youtube.com/channel/UCFTN-EU3umbz_0d0GFwk_Bw Stitcher: https://www.stitcher.com/show/selfheal-with-dr-irene TuneIn: https://tunein.com/podcasts/Health--Wellness-Podcasts/Self-Heal-(with-Dr-Irene)-p1421793/ Google Podcasts: https://podcasts.google.com/feed/aHR0cDovL3NlbGZoZWFsaW5nLm1pbmRzaGFyZWNvbGxhYm9yYXRpdmUubGlic3lucHJvLmNvbS9yc3M Deezer: https://www.deezer.com/show/2461592

Anthony, Bill and Leon are joined by Special Guest Paulie Loscalzo to talk about his journey to Drexel, The Triangle's resurgence and what to expect this same but new roster, the tentative schedule and who the starting five will be going into the 2023-24 season.

This episode features Matthew Loscalzo, Executive Director of People & Enterprise Transformation, Emeritus Professor of Supportive Care Medicine, & Professor Population Sciences at City of Hope. Here, he discusses physician burnout, his book that he's recently co authored with Linda A. Klein & Marshall Forstein - “Loss and Grief: Personal Stories of Doctors and Other Healthcare Professionals”, and more.

Due giorni di riposo dopo 16 di calcio no stop. Si tira il fiato prima del gran finale dei Mondiali in Qatar. Sono partite in 32, ne sono rimaste solo 8, con due grandi favorite, Brasile e Francia. Ma è già tempo di primi bilanci, con il numero 1 della Fifa, Gianni Infantino, che festeggia un record “mondiale” di spettatori in tv.

Health care professionals are human, and as humans we experience loss both in and out of work.  You'd imagine though that our professional expertise and experiences in helping patients and families cope with loss and grief would be helpful in managing our own personal losses.  Turns out, it's maybe not. That was the lesson I learned from reading a new book edited by Matt Loscalzo along with Marshall Forstein called “Loss and Grief: Personal Stories of Doctors and Other Healthcare Professionals”.  It's a collection of personal stories of a small number of health professionals, including Craig Blinderman and Susan Block, who have been struck by personal illness and loss. On today's podcast, we've invited Matt Loscalzo and Craig Blinderman to talk about their book and the process they used to create these stories, which all stood out for their openness in talking about things that we as healthcare professionals often keep so very private.   We also brought in Vickie Leff to talk about the work she does with Wellness Debriefings.  These debriefings create a safe outlet for health care professionals to talk about the feelings resulting from their work.  Vickie worked with CAPC to create tools, including a facilitator guide, to encourage clinicians and their organizations to adopt debriefings.  So take a listen and check out some of these resources for healthcare provider loss, grief, and wellness: Loss and Grief: Personal Stories of Doctors and Other Healthcare Professionals Dates & registration info about debriefings offered by CAPC The CAPC Debrief Facilitator Training Manual we developed: PDF Download. Jared Rubensteins' "Token of Appreciation" video A great website for dealing with loss and grief: refugeingrief.com SPONSOR: This episode of the GeriPal Podcast is sponsored by UCSF's Division of Palliative Medicine, an amazing group doing world class palliative care.  They are looking for physician faculty to join them in the inpatient and outpatient setting.  To learn more about job opportunities, please click here: https://palliativemedicine.ucsf.edu/job-openings

In this episode, I am joined by John LoScalzo, owner and chef of LoKo Cuisine.LoKo Cuisine is best known for their pop-up meals in collaboration with the Tampa Bay area's craft breweries, called "Eggs & Kegs." On scheduled Sunday mornings, John and his wife Stephanie Kojima are hard at work cooking inspired meals for the culinarily curious (and hungry) food and beer enthusiasts.And LoKo's meals always have a food, beer, or cultural "twist." Whether it's a meal themed after the flavors of Cigar City's Jai Alai IPA, or New England IPA with New England Surf & Turf, or his latest inspiration Bibimbap & Hip Hop, John always finds a creative theme for his meals. In our interview, John talks about how LoKo Cusine got started, his inspiration for LoKo's pop-up meals, and his thoughts on beer and food pairing.In this episode, you will again hear a segment I am calling “The Six Pack.” These are six questions to conclude the episode, all related to the beer industry and what the guest has learned in the industry. The “six pack” gives a little more information about Joe and his beer beliefs.You can listen to the podcast here, or on your favorite podcast platform. Remember to subscribe or follow so you don't miss an episode!Thanks for joining us in the journey of the BeerWise Podcast, hosted by Mark DeNote – editor of Florida Beer News.If you like the podcast, please tell someone. If you have constructive feedback or a guest you'd like to hear on the show, please email mark@floridabeernews.com or follow the “Contact Us” link on FloridaBeerNews.com.For more info about BeerWise, follow Florida Beer News on Facebook, Twitter, and/or Instagram.

Divakaran, S., & Loscalzo, J. (2017). The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics. Journal of the American College of Cardiology, 70(19), 2393-2410. https://doi.org/10.1016/j.jacc.2017.09.1064 --- Send in a voice message: https://anchor.fm/las-poderosas-celulas-nk/message

Can untreated elevated blood sugar levels contribute to anxiety and depression? Which blood sugar-related symptoms can therapists look out for in their clients? What can you do to reduce insulin resistance? MEET DR. RITAMARIE LOSCALZOhttps://drritamarie.com/ (Dr. Ritamarie) specializes in using the wisdom of nature to restore balance to hormones. She places a special emphasis on thyroid, adrenal, and insulin imbalances. Dr. Ritamarie founded the Institute of Nutritional Endocrinology to empower health and nutrition practitioners to get to the root cause of health concerns by using functional assessments and natural therapeutics to balance the endocrine system, the body's master controller. Dr. Ritamarie is trained and certified in the art of using whole, fresh plant foods in delicious ways to restore balance to hormones and body systems, and she's trained and certified other health and wellness professionals – doctors, nurses, nutritionists, health coaches — in the art of using palate-pleasing, whole fresh food as medicine. Visit https://drritamarie.com/ (her website), and connect with Dr. Ritamarie on https://www.facebook.com/DrRitamarieLoscalzo/ (Facebook), https://www.instagram.com/drritamarie/ (Instagram), and https://www.linkedin.com/in/drritamarie/ (LinkedIn). Listen to her https://reinventhealthcare.com/ (Reinvent Healthcare podcast) and https://drritamarie.com/books/ (read her books). IN THIS PODCAST:How does blood sugar impact mental health? Which blood sugar-related symptoms therapists can therapists look out for? How to treat and steady blood sugar levels How does blood sugar impact mental health?When the blood sugar is out of balance with symptoms [like] … cranky, irritable … are related not just to low blood sugar … but when I do the testing on people, most of them [actually have] high blood sugar but the sugar is not getting into the cells because of a condition called insulin resistance. (Dr. Ritamarie)Insulin is a hormone that transports sugar into the cells for the body to have energy. Cells can become insulin resistant over time if someone eats too much sugar too frequently. Therefore, they have high blood sugar, but low levels of cellular sugar. Sporadic blood sugar levels impact your memory, mood, attention span, ability to focus, as well as your production of serotonin and dopamine – happy hormones – in the gut and brain. Which blood sugar-related symptoms therapists can therapists look out for?Therapists should lookout for some of the following symptoms in their clients that could relate to imbalanced blood sugar levels: If a client cannot go for two hours between meals and snacks without feeling cranky, moody, or irritable. If a client still feels hungry after eating a full meal. If the client is prone to exhaustion in the afternoon. If a client struggles to get up and start their day without a cup of coffee. If a client is constantly craving sugar and carbohydrates. You have to look at the possibility of blood sugar [imbalances]. It is so overlooked … you know, the most common cause of sudden death from health failure is insulin resistance. (Dr. Loscalzo)How to treat and steady blood sugar levels1 – Observe diet Limit your intake of processed and highly refined food. Blood sugar imbalance leads to immune imbalance. The folks that have dysregulated blood sugar are going to have more problems with infectious diseases. (Dr. Loscalzo)2 – Be conscious of your vitamin and mineral intake. Highly sugary and processed foods can block or minimize the body's ability to absorb nutrients, vitamins, and minerals. Eat raw, healthy, whole foods wherever possible to ensure a higher vitamin content and take a good supplement. 3 – Reduce stress Cortisol, the stress hormone, seeks out glucose – sugar – in the body to put into the blood when the person is feeling stressed or anxious. Stress hormones cause a spike in blood sugar to help you run away from the stressor, like a lion. However, we...

Melissa & Austin talked to Jason "Loco" Loscalzo the Head Strength and Conditioning Coach for your Chicago Bears! See omnystudio.com/listener for privacy information.

Please join authors Babken Asatryan and Anwar Chahal, and Associate Editor Ntobeko Ntusi as they discuss the Primer article "Inflammation and Immune Response in Arrhythmogenic Cardiomyopathy: State-of-the-Art Review." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-hosts, I'm Dr. Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, associate editor, director of the Pauley Heart Center at VCU Health at Richmond, Virginia. Well, Carolyn this week, our feature discussion, we're not going to go with one of our original articles, but we are going to feature a primer and a primer is a state of the art review article. The topic is going to be on arrhythmogenic cardiomyopathy and we'll be looking at the role of inflammation and the immune response in arrhythmogenic cardiomyopathy. But before we get to that feature, how about we grab a cup of coffee and talk about some of the other articles in the issue? Would you like to go first? Dr. Carolyn Lam: I would, because guess what? I'm going to be talking about prescription opioids. We know these are a major contributor to the ongoing epidemic of persistent opioid use. What do you think is the incidence after cardiac implantable electronic device procedures? Greg, let's start with a Greg Hundley quiz. I'll give you multiple choice, how about that? Do you think it is 1%, 10%, 25%. 50%? Dr. Greg Hundley: All right, Carolyn, I'm going to guess here. I'm going to go 10%. Dr. Carolyn Lam: Smart. Well, guess what? Today's paper actually gives us insight into that question, it's from Dr. Frankel from the hospital of the university of Pennsylvania and his colleagues, and these authors performed a retrospective cohort study using data from a national Administrative Claims Database from 2004 to 2018 of patients undergoing cardiac implantable electronic device procedures. Adult patients were included if they were opioid naive during the 180 day period before the procedure and did not undergo another procedure with anesthesia in the following 180 days. Dr. Carolyn Lam: Persistent opioid use, which is what we're interested in, was defined by filling an additional opioid prescription more than 30 days following the procedure. So, here's your answer. Of the more than 143,000 patients meeting these inclusion criteria, 11%, so you were right Greg, 11% filled an opioid prescription within 14 days of surgery. Among these patients, persistent opioid use occurred in 12.4% of patients, 30 to 180 days after surgery. The likelihood for developing persistent opioid use was increased for patients who had a history of drug abuse, pre-operative muscle relaxant or benzodiazepine use or opioid use in the prior five years. Also, patients who have prescribed more than 135 milligrams of oral morphine equivalence had a significantly increased risk of persistent opioid use. Dr. Carolyn Lam: Now, this is important because all physicians who perform cardiac implantable electronic device procedures and care for these patients should be aware of the risk of persistent opioid use. This is discussing in editorial by Dr. Kandil from UT Southwestern. Dr. Greg Hundley: Very interesting Carolyn, so connecting sometimes the prescription use of opioids after cardiac implantable electronic devices. Great presentation. Well, my first paper comes to us from the world of preclinical science and it's from our prior editor in chief Dr. Joseph Loscalzo from Brigham and Women's Hospital and the Harvard Medical School. So Carolyn, interferon gamma, producing CD4 positive and CD8 positive T-lymphocytes, have been identified as the predominant pathological cell subsets in human atherosclerotic plaques. Dr. Greg Hundley: While the immunological consequences of these cells have been extensively evaluated, their interferon gamma mediated metabolic effects on endothelial cells remains unknown. So Carolyn, the purpose of this study was to determine the metabolic consequences of the T-lymphocyte cytokine interferon gamma on human coronary artery endothelial cells. Dr. Carolyn Lam: Interesting. So what did Dr. Loscalzo and colleagues find? Dr. Greg Hundley: Right, Carolyn. So, the authors found that interferon gamma impairs endothelial glucose metabolism via altered tryptophan metabolism while depleting NAD plus, which results in a metabolic shift toward increased fatty acid oxidation, and therefore, Carolyn, this work suggests a novel mechanistic basis for pathologic T-lymphocyte endothelial interactions in atherosclerosis, mediated by interferon gamma, linking endothelial glucose, tryptophan, and fatty acid metabolism with NADH and ATP generation and their adverse endothelial functional consequences. Dr. Carolyn Lam: Oh, very nice, Greg. Thank you. The next paper describes a comprehensive characterization of cardiomyopathy caused by filament C truncating variance. Dr. Greg Hundley: Whoa. Okay, Carolyn. Now what is filamin-C? Dr. Carolyn Lam: I thought you may ask and I wasn't going to quiz you, see Greg? The filamin-C gene can cause a striated muscle protein that crosslinks actin and anchors cell membrane proteins to the cytoskeleton, sarcolemmal and sarcomere Z-disc. So, the co-corresponding authors of today's paper Drs. Mestroni and Taylor from University of Colorado, Denver Anschutz Medical Campus, analyzed longitudinal clinical data from an international multicenter cohort of 85 carriers of this filamin-C truncating variants. And this is what they found. Dr. Carolyn Lam: First, the cardiomyopathy associated with filimin-C truncating variants appeared to be a disease with heterogeneous phenotypic presentation, ranging from typical dilated cardiomyopathy to arrhythmogenic, right ventricular cardiomyopathy, and with frequently overlapping forms. Dr. Carolyn Lam: Number two, left ventricular ejection fraction was associated with the risk of death, either all cause or non-arrhythmic, heart transplantation, or LVAD, but not with the risk of sudden cardiac death or major ventricular arrhythmias, highlighting the need for alternative strategies of stratification of the arrhythmic risk in these patients with the filimin-C truncating variant cardiomyopathy. Dr. Carolyn Lam: And number three, this cardiomyopathy was associated with a high risk of ventricular arrhythmias with frequencies of life-threatening ventricular arrhythmias, not significantly different from things like Lamin and desmoplakin cardiomyopathy. Dr. Greg Hundley: Well, Carolyn, just fantastic. My next paper comes to us from Professor Lena Claesson-Welsh from Uppsala University and Carolyn, palmdelphin belongs to the family of paralemmin proteins implicated in cytoskeletal regulation and single nuclide polymorphisms in the palmdelphin locus that result in reduced expression are strong risk factors for development of calcific aortic valve stenosis, and predict the severity of the disease. Dr. Carolyn Lam: Wow, interesting. Palmdelphin, great. So tell us, what did they find and what are the clinical implications please? Dr. Greg Hundley: Right, Carolyn, great question. So first, calcific aortic valves stenosis patients with the single nucleotide polymorphism RS754 3130 express reduce palmdelphin levels in valve endothelial cells, which shows hallmarks of palmdelphin deficiency, such as loss of cytoplasmic RanGAP1, altered nuclear morphology and nuclear rest of P53 of P21. Carolyn, second, gene-regulatory changes affecting actin reorganization, are detected in seemingly healthy regions of calcifying bowels, in agreement with disturbed actin-dependent processes, being an early event, instigating the calcific process. And so Carolyn, the take home message is that palmdelphin is prominently expressed in endothelial cells and the presence of the palmdelphin single nucleotide polymorphism correlated both with a Barrett endothelium and calcific aortic valve stenosis suggesting that endothelial cell dysfunction is essential in development of calcific aortic valve disease. Dr. Carolyn Lam: Oh, wow, wow. Thank you for translating that into the clinical implication. Thanks Greg. Let's maybe discuss what else is in today's issue. There's a prospective piece by Dr. Kirchof entitled “In Patients With Recently Diagnosed Atrial Fibrillation, Think Anticoagulation And Rhythm Control.” There's an exchange of letters between Drs. Liao and Hakala regarding the article Cardiovascular Risk Factor Trajectory Since Childhood And Cognitive Performance In Midlife, The Cardiovascular Risk In Young Finns, study. Dr. Greg Hundley: And Carolyn, I've got a research letter from Professor Ramin entitled “Association Between Sarcomeric Variants In Hypertrophic Cardiomyopathy In Myocardial Oxygenation, Insights From A Novel Oxygen-Sensitive CMR Approach.” Well, how about now we get onto that primer feature discussion relating to arrhythmogenic cardiomyopathy? Dr. Carolyn Lam: Yay. All right, let's go, Greg. Dr. Greg Hundley: Well, listeners, we are now onto our feature discussion and this week we've got a different aspect to the feature discussions. We're going to work through a review article and what we call as a primer. It's one of our state-of-the-art family of publications, where we take a topic and perform a review on a new evolutionary concept that might be occurring in a particular field. This week, we are going to discuss arrhythmogenic cardiomyopathy and we have with us two of the authors of this primer, Dr. Babken Asatryan from Bern, Switzerland and also Dr. Anwar Chahal from Lancaster, Pennsylvania. And of course, as always, we invite one of our associate editors and we have with us this week Ntobeko Ntusi from South Africa. Welcome gentlemen and Babken, let's start with you. Can you give us just a little bit of review regarding arrhythmogenic cardiomyopathy? We hear that term as opposed to arrhythmogenic right ventricular cardiomyopathy, and then maybe also, what are the underlying fundamental histopathologic and pathophysiologic findings associated with this disease? Dr. Babken Asatryan: Thank you, Greg. It's really an absolute pressure being here and thank you for your invitation again. So arrhythmogenic cardiomyopathic is genetically-determined heart disease and the common cause of sudden cardiac death in individuals younger than 40 years of age, it's characterized pathologically by fibrosis and/or fibro fatty infiltration of the myocardium. This infiltration provides a substrate for electrical and stability and leads to ventricular arrhythmias ranging from isolated premature ventricular contractions to sustain ventricular tachycardia and ventricular fibrillation. Live ventricular arrhythmias are cardio manifestations of the orthogenic cardiomyopathy, and they typically occur at early stages of the disease, preceding pathological and functional abnormalities. We call that a concealed stage of the disease. Dr. Babken Asatryan: The typical form for arrhythmogenic cardiomyopathy, which has been previously termed as arrhythmogenic right ventricular cardiomyopathy, primarily affects the right ventricle and has been recognized for decades. Following implementation of postmortem autopsy, increased use of contrast, enhanced cardiac MRI, and improved understanding of the genotype phenotype correlations, more recently cases with more pronounced left ventricular involvement have been discovered as well as cases with biventricular involvement of the disease. Dr. Babken Asatryan: Nowadays, we believe that around 60% of cases have also left ventricular involvement, even if they're diagnosed based on the 2010 task force criteria for arrhythmogenic cardiomyopathy. Causative variants in desmosomal genes are identified in about 60% of patients with typical arrhythmogenic right ventricular cardiomyopathy. Dr. Babken Asatryan: Recently, there have been studies reporting non-desmosomal gene variants in patients with arrhythmogenic right ventricular cardiomyopathy, as well as in those left ventricular and biventricular forms of the disease. But the left ventricular form is quite new to us, so we are learning a lot every day about this disease. Dr. Babken Asatryan: The pathogenesis of this condition appears to be quite complex. We know that these pathogenic variant in desmosomal genes can initiate several pathways and these could be gene dependent. What we do know, that these eventually lead to fibrosis and fibro fatty infiltration of the myocardium, which is the hallmark feature of arrhythmogenic cardiomyopathy. Dr. Greg Hundley: And patients present generally when, in terms of lifespan? Dr. Babken Asatryan: So, patients present in between 30 to 40 years of age, there's a typical presentation for arrhythmogenic cardiomyopathies but young presentations are also common nowadays, particularly. So, programs in families, they usually present 30 to 40 years of age. But in families, we do discover patients who have typical arrhythmogenic right ventricular cardiomyopathy or left and right ventricular involvement were younger at age, but they still need the criteria. Dr. Greg Hundley: And then when we diagnose this condition, do we also need to think about, at least clinically, looking for other affected individuals within a family? Dr. Babken Asatryan: Absolutely. So most of the arrhythmogenic biventricular cardiomyopathy, arrhythmogenic left ventricular cardiomyopathy cases are autosomal dominant diseases. So, this means if an individual carries a pathogenic variant in one of the genes responsible for the condition, the likelihood that the first degree family members will carry the same variant is about 50%. The disease however, presents with reduced penetrance and variable expressivity. Some of the family members may have just arrhythmias and others may develop arrhythmias and structural heart disease. And some of the individuals who carry pathogen occurrence in desmosomal are the genes responsible for the condition may not show phenotype at all. So, that makes the decision-making in families quite challenging. Dr. Greg Hundley: Very nice. Well, thank you so much Babken and now, we're going to turn to one of your co-authors, Anwar and Anwar, in this primer, you start to present a new sort of theme, that inflammation actually may play a role in this disease, at least in terms of adverse events. Can you describe a little bit what your team was thinking here and what took you in this direction and what are some of the research that you've revered here that supports this new line of thinking?   Dr. Anwar Chahal: Thanks, Greg and Ntobeko, for first, the kind invitation to come on this podcast. I must add that I normally listen to the podcast and very much enjoy it, so it's a great honor and privilege for us. Dr. Anwar Chahal: Let me contextualize it, I think it's important to think about what are problems are when we evaluate cases, whether that's the program or the family members, and try to determine what's actually going on. There's been a number of changes over the last 15 years that really evolve around a better understanding and the availability of multimodality imaging, which has altered the way we evaluate these cases. If you look at the 2010 taskforce criteria, for example, they talk about volumetric changes and injection fractions by echo or MRI, and even ventriculogram synapse on fluoroscopy, which I don't think many people do anymore, but they don't mention gadolinium enhancement, and there is an updated version that will come out and talk about that, and the advantages of MRI and even contrast-enhanced CT, and now 18F-FDG, CT PET imaging. Dr. Anwar Chahal: So, the patient journey and the problem that we face is that actually some people present with very unusual features, chest pain, troponin rise, undergo coronary angiography, normal coronary arteries, or unobstructed coronary arteries. We put them through MRI scanners and we see a little bit of gadolinium enhancement. We follow them over the next five years or so, and it develops into taskforce criteria, positive ARVC. So, that's the sort of clinical angle where we've started to see this. Dr. Anwar Chahal: As we put people through scanners, we see the hearts lights up on PET scanners, pretty reproducibly and reliably, that tells us that there's some inflammation there. We look back into the literature and actually very, very early work that was done, autopsy-based, some of it endomyocardial biopsy-based describing lymphocytic infiltrates. Usually that's dry, as you say, or sterile, but there have been reports of even viral pathogens. Dr. Anwar Chahal: That's where it stirred this debate up for us about whether there's this signal that we're seeing there, what is it? What's actually going on? It raises a question, we recognize the other mechanisms, the fiber fatty replacement, the apoptotic pathways, that contribute to that. But there's such variable expressivity with this disease. It's a difficult disease to pin down and it raises a question. What are these other effect modifiers? Is there something else that we do not recognize? And that's really what's driven this. Dr. Anwar Chahal: Our group of co-authors are leaders in the field. Some of them are colleagues in veterinary medicine, Dr. Anna Geltser, and we work together on boxer dog patients. So, she is a practicing vet and a scientist, and has lots of boxer dogs with arrhythmogenic cardiomyopathy. We've been looking at how we could utilize that as a model to test some of the findings that we have in humans and pioneering work really by Bob Hamilton in Toronto, in this paper where they described anti-DSG2 antibodies, which were found not only in humans, whatever the underlying genotype, but also in boxer dogs with arrhythmogenic cardiomyopathy. And that's been followed up with work from Europe, describing anti-heart antibodies, anti-intercalated disk antibodies. Dr. Anwar Chahal: It doesn't really matter what the genotype is, but we're seeing these antibodies there and we're seeing these positive scans indicating inflammation. So the big question is, is this inflammation of primary insult or is it secondary? Is it that the heart in somebody with a genetic cardiomyopathy is predisposed, maybe the remodeling is affected. Bob Hamilton thinks this is probably the best explanation to explain why, whatever the genotype, that these antibodies were positive, that actually that myocardium becomes exposed. The epitope of DSG is now exposed to the immune system, which mounts an antibody response, and hence you see the rise in these antibodies, but it's possible it could it be primary as well. With COVID, and this is a bit of a stretch, so just bear with me there, with COVID we've been recognizing that there's myocardial injury. Dr. Anwar Chahal: There's not as much myocarditis as we expected, but there's been, with virus SARS-CoV-2, we know regular human coronavirus is a recognized cause of viral myocarditis. So, the question really arose are we going to see a lot more of this myocarditis? In our lab discussion, it was, "Well, do you think we're going to see something similar in that we've seen with arrhythmogenic cardiomyopathy, these genetically predisposed individuals are more likely to get invaded? Now, we haven't really seen that with COVID and I won't delve too much into it, but going back to the classical viral infections that we see with myocarditis, here's a really, really interesting biological link. Most of them invade through the desmosome, so with SARS-CoV-2, we see the ACE2 receptors as the way the virus really invades. But with these regular coxsackie virus, for example, parvovirus, a lot of them invade through the desmosome, and that's where we thought, here's a link. Dr. Greg Hundley: Very nice. Ntobeko, you see a lot of papers come across your desk. What attracted you to this group of investigators and this particular review article? Dr. Ntobeko Ntusi: Thank you very much, Greg. I want to start by congratulating Babken, and Anwar for a really fantastic submission, which as an associate editor, was an absolute pleasure to handle. There really are six things that stood out for me about this article. The first one really relates to the question that you ask Babken, which relates to the nomenclature and people have traditionally thought of this is a disease of the right ventricle. I think it's now timely to consider a clear change in nomenclature, that recognizes not only right ventricular involvement, but also left ventricular involvement. And the common finding of biventricular disease in patients with ACM. Dr. Ntobeko Ntusi: The second really important contribution for me from this primer was that we've always thought of arrhythmogenic cardiomyopathies as a genetic disorder with abnormalities in the genes, encoding components of the desmosome. Many groups recently, including our own group that described novel mutations for arrhythmogenic cardiomyopathy in adhering to poultry and other genes outside of the desmosome are showing that the genetic underpinnings are much wider. But the key contribution here is really the consideration of the centrality of inflammation to the pathogenesis of this disease. Anwar has spoken to some length about that, so I won't rehash those comments, but for me, what is key for future work in this area is really to clarify whether the inflammation, as in with many other forms of cardiovascular disease, is merely an epiphenomenon, or whether it plays a critical role in the causal pathway for the phenotypes that we see. Dr. Ntobeko Ntusi: The next important feature for me was the review of the literature and evidence in the association with myocarditis. So, we've seen lots of case reports and small case series showing young people presenting with myocarditis and meeting either the Dallas criteria histologically, or the Lake Louise criteria on imaging, and then subsequent genetic testing confirming the diagnosis of an arrhythmogenic cardiomyopathy. I thought for the first time with quite a compelling review of the link between these two. Dr. Ntobeko Ntusi: The fourth important contribution relates really to the contribution of imaging modalities, both in diagnostics, but critically in risk stratification for this clinical entity. And for me, the importance of cardiovascular magnetic resonance, either with planimetric mapping or late gadolinium enhancement to really add to our ability to predict future events. Dr. Ntobeko Ntusi: Then there's been quite a number of publications in the last five years that have clarified our understanding of the at risk patient with arrhythmogenic cardiomyopathy who's likely to suffer a sudden cardiac death event. This tends to be somebody who was young, who was male, who has a history of documented non-sustained ventricular tachycardia or a history of syncope and on ECG, quite extensive T wave inversion. So again, this is nicely reviewed, and we think about those as candidates who'll benefit from implantation of an ICD. Dr. Ntobeko Ntusi: Then I thought for me, the last really nice contribution from this piece was the review of advancing our understanding of the hot phase. So in all forms of heart muscle disease, we speak of the presentation of patients with the chest pain syndrome, with a troponin leak, but unobstructed coronaries. On further investigation, we don't really find any other evidence of an inflammatory event. We call this a hot phase. And in some case reports in small case series, endomyocardial biopsy has revealed the association of these, whether in TCM, HCM, or arrhythmogenic cardiomyopathy with lymphocytic infiltration. I thought this was all very nicely reviewed. Dr. Ntobeko Ntusi: So, the question that really left me with having read this review, was whether in the future, we may actually need to consider targeting inflammatory pathways as a therapeutic target in this heart muscle disorder. Thanks Greg. Dr. Greg Hundley: Yes. Thanks so much in Ntobeko. You've really led us to the next question that I'm going to ask both Babken and Anwar, you've discussed where do you feel this field is moving and what is the next study or series of studies we need to perform. Babken, first you, and then Anwar. Babken, what do you think is the next study to be performed in this space? Dr. Babken Asatryan: I so much agree with Ntobeko, that perhaps understanding better what can be targeted in these patients, in order to prevent development of phenotype or least to prevent cardiac events, is perhaps the most important next step. In our first figure, we have summarized this potential mechanisms, involving inflammation leading to with arrhythmogenic cardiomyopathy in these patients. We have also highlighted the potential mechanisms that perhaps in the future can be targeted. This could include both targeting the inflammatory cytokines, as well as the primary agents that cause the myocardial inflammation in patients, depending on the results that we will receive over the next years and perhaps animal models should be the next step to better understand how similar arrhythmogenic cardiomyopathy phenotype, where inflammatory contributors to the phenotype are important. And then we can understand whether this can be the same in humans as well. Dr. Greg Hundley: Very nice. And Anwar, do you have anything to add? Dr. Anwar Chahal: Yes. So, agree with that. I guess I would add what are we doing to try to help decipher this? So some of the work that we're doing, I mentioned earlier with the boxer dog patients, who have arrhythmogenic cardiomyopathy. So some of the aspects that we're actually looking at is taking swab cells to see if we can phenotype as a alternative tender myocardial biopsy. And one of the co-authors, Angeliki Asimaki, really pioneered that as a alternative tool because the desmosis are ubiquitous and this may help us phenotype patients better. But also, we want to look at using that as a tool in the pheno copies of arrhythmogenic cardiomyopathy. So we would advocate, re-phenotyping people as well as possible and trying to use some of these techniques. Dr. Anwar Chahal: The next thing we're really looking at is antibody based tools, either working with collaborators, who've already described these antibodies such as anti-DSG2, anti-heart antibody, and anti-skeletal disc to see if we can develop those and perhaps identify others in both human and ox models. And that will then hopefully open the way for us to develop therapeutics that may be able to target those and address that, and maybe use these antibodies as markers to see disease progression, or halting of disease. Dr. Greg Hundley: Very nice. Well listeners, we want to thank Dr. Babken Asatran from Bern, Switzerland, Anwar Chalal from Lancaster, Pennsylvania, and our own associate editor, Ntobeko Ntusi from South Africa, really helping us see this new scientific consideration regarding the potential role of inflammation in causal pathways of adverse manifestations of arrhythmogenic cardiomyopathy. Well, on behalf of Carolyn and myself, we want to wish you a great week and we will catch you next week on the run. This program is copyright of the American Heart Association, 2021. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more visit ahajournals.org.

Welcome to Episode 12! The Chicks are back at it and we are trying to tackle the concept of shooting space yet again. Alex is back too, giving us his opinion on the rule. I think we really need a professional opinion on it. This week it's all about putting sticks first, crease dives, and whistle blowing. Enjoy! Alex's Instagram: alex_loscalzo24 Feel free to send us any of your own stories at chickswithstickspodcast@gmail.com and check us out on Instagram @chickswithstickspodcast too! Enjoy :) Linktree: https://linktr.ee/chickswithstickspodcast --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Welcome to Episode 11! (Delaney's jersey number!!) Hitting walls, getting hit and how hits in men's and women's lacrosse differ. The chicks have their friend Alex Loscalzo onto the pod to compare and contrast the two versions of their favorite sport. This episode is definitely more light hearted than most, we hope you enjoy the three of us shooting the breeze. We actually talked for so long we decided to split the convo up into two episodes for your enjoyment. In this episode Alex, Ash, and Delaney wrestle with the shooting space call for about the millionth time. Happy listening! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Our special guest, Ritamarie Loscalzo, DC, will discuss the real global pandemic: blood glucose dysregulation. _________________________________________ Welcome to Humanized! Each week, we feature top experts in personalized health and functional medicine through engaging interviews and presentations. You'll get practical advice on diet and nutrition, lifestyle, toxins and disease, hormone imbalances, nutrient deficiencies, inflammation, digestive health, mental health, the fast-changing world of genomics, and so much more. All presentations are available as videos, podcasts or transcripts – whichever form is most convenient and enjoyable for you! Visit us at: https://humanizedhealth.com Subscribe to get weekly updates at: https://omniform1.com/signup/v1/5e736dfb8a48f751fdd6aa8a_604bd3c799f0b7086d1de9a4.html

ZOOM - 90 MINUTI IN MEZZO AI FATTI - A. D'ANNA - D. LOSCALZO, 12-01-21 h. 10.35 Seconda (e ultima, per il momento) puntata dedicata alla difficile transizione americana. Antonino D'Anna ne parla con Donato Loscalzo in collegamento da New York. Quale futuro per un'America diversa rispetto all'immagine che ne abbiamo? E quale sindaco per la Grande Mela dopo Bill De Blasio?

Joseph Loscalzo, MD, PhD, MA, is the Hersey Professor of the Theory and Practice of Medicine and Soma Weiss MD Distinguished Chair in Medicine at Harvard Medical School,  Chairman of the Department of Medicine and Physician-in-Chief at Brigham and Women's Hospital. Dr. Loscalzo completed his MD from the University of Pennsylvania and training in internal medicine and cardiology from Brigham and Women's Hospital. He has authored over 1,000 scientific publications, has authored or edited 51 books, and holds 32 patents for his work in the field of nitric oxide, redox biology and vascular biology. Dr. Loscalzo has been awarded the George W. Thorn Award for Excellence in Teaching at Brigham and Women's Hospital, the Distinguished Scientist Award and the Paul Dudley White Award from the American Heart Association and the MERIT Award from the NIH to name a few. Dr. Loscalzo is the former Editor-in-Chief of Circulation, currently the editor at large at the New England Journal of Medicine and a current senior editor of Harrison's Principles of Internal Medicine. Mentors are not just found in people, mentorship is a mindset, a learning mindset. Today, Dr. Joseph Loscalzo shares how he has found mentors not only in those physicians whom he has aspired to become like, but also in the mistakes he has made. And while these mentors may be more anonymized than the rest, they are absolutely as important as the personal interactions. He reminds us of a statement by Winston Churchill “Success is not final, failure is not fatal. It's the courage to continue that counts”. And so rather than trying to avoid failure and become successful at every step, he encourages us to embrace challenges, because it is those challenges that we encounter which will foster our growth in every stage of our career. Pearls of Wisdom: 1. It's the challenges that help us grow. It's the times we aren't as successful that make an impression. And we should seek comfort in facing failures and learning from them. 2. Mentors are not just people, mentorship is a mindset: A learning mindset. Our advisors, peers, students and even our mistakes can be mentors on our journey. 3. Shared success is more important than solo success and has a longer lasting effect because of its propagating features. Collaborate together to succeed.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.27.270173v1?rss=1 Authors: do Valle, I. F., Roweth, H. G., Malloy, M. W., Moco, S., Barron, D., Battinelli, E., Loscalzo, J., Barabasi, A.-L. Abstract: Polyphenols, natural products present in most plant-based foods, play a protective role against several complex diseases through their antioxidant activity and by diverse molecular mechanisms. Here we developed a network medicine framework to uncover the mechanistic roles of polyphenols on health by considering the molecular interactions between polyphenol protein targets and proteins associated with diseases. We find that the protein targets of polyphenols cluster in specific neighborhoods of the human interactome, whose network proximity to disease proteins is predictive of the known therapeutic effects of polyphenols. This finding allows us to predict that rosmarinic acid (RA) has a direct impact on platelet function, representing a novel mechanism through which it could affect cardiovascular health, and experimentally confirm that RA inhibits platelet aggregation and alpha granule secretion through inhibition of protein tyrosine phosphorylation. Our framework represents a starting point for mechanistic interpretation of the health effects underlying food-related compounds, allowing us to integrate into a predictive framework knowledge on food metabolism, bioavailability, and drug interaction. Copy rights belong to original authors. Visit the link for more info

Dr. Michelle Morse is an assistant professor at Harvard Medical School and cofounder of EqualHealth. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. M. Morse and J. Loscalzo. Creating Real Change at Academic Medical Centers — How Social Movements Can Be Timely Catalysts. N Engl J Med 2020;383:199-201.

This week’s episode is special: we have the former and current Editors-in-Chief of Circulation on Circulation on the Run. Join Dr Amit Khera, Digital Strategies Editor of Circulation, as he speaks with Dr James T. Willerson, Editor-in-Chief from 1993 to 2004; Dr Joseph Loscalzo, Editor-in-Chief from 2004 to 2016; and Dr Joseph A. Hill, the current Editor-in-Chief. They will discuss the history of Circulation and how it continues to evolve. TRANSCRIPT Dr Amit Khera: Hi, this is Amit Khera. I'm digital strategies editor for Circulation from UT Southwestern Medical Center in Dallas. Today we have a very special Circulation on the Run. We have three Editors-in-Chief from Circulation. First, we have Dr James Willerson, who was the Editor-in-Chief from 1993 to 2004. He's a President Emeritus at the Texas Heart Institute. We also have Dr Joseph Loscalzo, who was Editor-in-Chief from 2004 to 2016, the Chairman of Department of Medicine from Brigham and Women's Hospital. And finally, Dr Joseph Hill, the current Editor-in-Chief, the Chief of Cardiology at UT Southwestern Medical Center. Welcome, gentlemen. Dr Joseph Hill: Thank you. Dr James Willerson: Thank you. Dr Joseph Loscalzo: Thank you. Dr Amit Khera: Dr Willerson, I must say, looking over the tenure prior to Dr Loscalzo, you had one of the longest tenures ever as Editor-in-Chief of Circulation, and certainly a lot happened in the practice of cardiology during that period. It was a really formative period in cardiology. As you think back, what were some of the most important topics that you covered during that time as Editor-in-Chief, thinking about the evolution of cardiovascular care and science at that time? Dr James Willerson: You have to remember, there have been many editors at Circulation. We all build on the shoulders of others, certainly I did. I really wanted Circulation to be the premier cardiovascular journal in the world. I wanted it to be much like the New England Journal of Medicine, but the New England Journal of Medicine Circulation of Cardiology. I wanted to publish it every week. We got permission to do that. That wasn't easy, but we were fortunate. I've been accused of wanting to publish it every day. There's actually some truth to that. I didn't make that. I didn't try very hard. I wanted to be able to present the information, important information, to everybody who cared about cardiovascular medicine: physicians, scientists, students, nurses, those who cared for people, and I wanted to do it frequently. I wanted to publish it quickly. So, we had some success with that. There are many other things that are well-known to the other editors, all of whom have built before me and after me, and I'm very proud of them. Dr Amit Khera: Well, thanks for that. And certainly, as you pointed out, this has been an evolution where you took the gauntlet, if you will, from the people before you, and then built on that and had many advances. I guess after you, Dr Loscalzo, you I think did have the longest tenure if I saw of any of the editors and similarly, a lot of evolutions in cardiovascular care and a lot in science, particularly during your time. Tell us a little bit about any particular papers or topics that you focused on, or that really were revolutionary in the cardiovascular space during your tenure. Dr Joseph Loscalzo: I'll pick up where Jim left off and just make the case that as you're suggesting, I mean, there's sort of been a natural transition of the kind of science that Circulation has been publishing over the tenure of the three editors here today. Before Dr Willerson, it was largely physiology and excellent clinical science. Jim really expanded the scope of what Circulation published to begin to put in press in its pages, fairly basic and translational science as well. I picked up from what he'd laid the groundwork for to expand the scope of that science. And as you know, expand it to the point that we had to develop daughter journals that would pick up the mantle in each of these increasingly subspecialized areas. So, it's hard to think about those papers that I found have the greatest impact because every field had several of them in my several years as editor. As you know, the subspecialty journals that we established, which remain active to the current time, are also broad in their scope from outcomes based research to genomics and proteomics insistence, cardiovascular medicine, to everything in between, imaging, intervention, heart failure, and electrophysiology to arrhythmias. Each of these was led, and continues to be led, by outstanding leaders in their subspecialty fields. I think the beauty of Circulation in contrast to even fine journals like the New England Journal of Medicine, is that Circulation has been able to put on its pages those studies that really do span quite a spectrum. We don't shy away from very basic studies. That actually began with Jim, I must say, because that wasn't the case previously. And of course, we move right through to epidemiology and outcomes based research. And the impacts have been broad in each of those fields, as witnessed by the excitement and uptake of the journal, measured however you wish, by impact factor, or citations, or the frequency with which it's referred to in the lay press. So, I think that tradition certainly continues under the current editor with papers of extraordinary impact. Dr Amit Khera: Thanks for that. I think your point about the evolution of science over time from Dr Willerson and certainly during your tenure and beyond to the breadth of Circulation currently. You also touched on the subspecialty journals. That happened in your watch and that was quite a marked change in cardiovascular medicine to have that explosion of new journals, if you will. What do you think the impact of those subspecialty journals has been for the cardiovascular field? Dr Joseph Loscalzo: We struggled with the idea about whether or not we should pursue that kind of fragmentation. What really pushed us was the fact that the acceptance rate remains quite low, in those days, probably eight or so percent range at its nadir. So, we were rejecting a lot of really excellent papers which wound up in competitor journal pages, that we would like to have accepted and been given the scrutiny of the careful reviews and editorials that accompany papers accepted by Circulation. We felt the best way to do that under the circumstances was to create these daughter journals. They succeeded, in many respects, beyond our wildest imagination. The numbers of papers that were published in the family increased, I think in the first two or three years, by at least 2-to 3000. So, that really speaks to the fact that we kept the best papers in the family. We gave them the right kind of audience. Some of these would have been too technical or too highly specialized to have been published in Circulation proper, but certainly of the highest quality and of significant relevance to the subspecialist. So, we think that it was a successful experiment. Now it's sort of become tradition. I think that the question that will always come up, of course, is can we fragment things more? I would say one of the best reasons to make the case that this was a successful experiment is that if imitation's the sincerest form of flattery, the New England Journal is now going to start three subspecialty journals. In fact, in my role now as an editor of the New England Journal, editor-at-large, they asked my input in how to design those daughter journals and what to expect from them. Dr Amit Khera: Well, I think that's a great point. It certainly has been a resounding success and as you pointed out, imitation is the best form of flattery. I'm going to pivot now to Joe Hill. Dr Hill, you have certainly been the beneficiary of all the great work that these two editors have done in the past. You've inherited a very successful journal and also have crafted your own vision for where you want Circulation to go in your mark. Tell us a little bit about some of the new initiatives you've tried to implement, leveraging on these past successes. Dr Joseph Hill: Thank you, Amit, it's an honor and a privilege to be in this conversation, frankly. I mean, Dr Willerson made this a weekly journal. That was back in the day when FedExes were flying around. Everything was paper. That kind of volume with that technology is impressive. And Dr Loscalzo, who has been a friend and mentor for many, many years, spearheaded the subspecialty journals, as we just heard, and took the journal to yet new heights. Each of you has been a pioneer and we've been fortunate to put together a team that I think has moved in exciting directions. We've leveraged technology now, such that we have our video conference meetings. We meet in a video conference with editors from 17 different countries. We have a third of our editors in Dallas, where I live, a third in the US outside of Dallas, and another third in 16 other countries. It turns out we alternate the time of that meeting each week because there's no single hour of the day that works around the globe, so we move it around to capture Asia or to capture California in alternating weeks. That has been a thrill and, honestly, I believe a robust success. We have leaders on the ground in all these different countries. We have a highly diverse team across the different subspecialty domains of cardiology, across different geographic regions, across race and sex and gender lines. It is an amazing team. And Amit, who leads our robust digital efforts, including this podcast and our efforts on social media, again, the opportunity now in the 21st century to take these initiatives forward has been a real privilege. Dr Amit Khera: It's ironic that Circulation was doing Zoom before everybody else was in the modern era. I'm going to pivot back to Dr Willerson. As Dr Hill just mentioned during your tenure how the volume of papers was handled, FedEx and sort of the nature of the journal publishing process. And now in the modern era, we have so much different information. We have a huge volume of journals. We have online, we have Twitter, we have podcasts. We have people that are consuming information in so many different ways. Tell us from your perspective, what's the role of the scientific journal currently and how has it changed at all in the last few decades? Dr James Willerson: It's always going to continue to evolve. It's about as good as it can be right now with Dr Loscalzo and Dr Hill's leadership, and I'm really proud of them. There'll be more. We can't even imagine what it will be in two or three years. Of course, it'll be better and better, faster, almost momentary. Thank you, Dr Hill. Dr Amit Khera: Thank you for that. I think we all look forward to seeing how this evolves more rapid information, rapid turnaround. I'm certain that will change. Dr Hill, you had a comment on that? Dr Joseph Hill: We live in an era now where peer review is under attack in many ways and pre-print journals, blogs and so forth. And one of the things that I've really seen, and we've all seen, is how the peer review process, and we're all authors, right, we live on the other end of that stick, but it really is important. It makes a big difference. And people who are anxious to accelerate that process, I totally get it. We work very hard to do that. At the same time we, following the traditions here, have an intentionally redundant review process where every paper is evaluated by multiple editors and multiple peer reviewers. On a number of occasions, we've avoided a pothole, or we've improved a paper many, many times. And that is something that has really been impressed on me that I think people who aren't on this side of the editorial fence might not appreciate as much. Dr Amit Khera: I think that's an important point about sort of the rigor about the way that articles come out in Circulation. And Dr Loscalzo, maybe as an extension of the last question, what do you see as some of the challenges going forward or opportunities for Circulation? You think about where it's been, but what are some of the things that you look forward to for Circulation in the future and what are some of the things you're concerned about? Dr Joseph Loscalzo: Well, I too am concerned about this issue of peer review being under attack, and I'm particularly concerned about it for papers that have direct clinical impact. A good example of that concern, of course, are papers published, or at least publicly released, on non-peer reviewed websites like the archive sites because of their importance in the COVID epidemic, potentially. We all know of cases of drugs, at least in test tubes, with cultured cells and viruses appear to be effective that have adverse clinical consequences. So that, and more than in any other sphere of science, ensuring that proper peer review from as many perspectives as possible is always a part of the process is absolutely critical for clinical medicine. And to me, the threat that this need for acceleration and rapid peer review poses and the sort of socialization of the transmission of scientific information that we're all interested in doing really has to have the brakes put on it a bit for the clinical science that the journal represents for this very important reason. Not to say we want to slow things down, we want to make sure that the best possible reviews are performed before we release it to the public. I know that, as Joe was pointing out, one of the most exciting parts of the role of when I led the journal was the weekly meeting. We had a face-to-face meeting because all of our associate editors, save one, was actually physically proximate and they could travel to our conference room. But it's a wonderful exercise to have people of very different perspectives, from basic scientists, to clinical electrophysiologists, to outcomes researchers, make comments on papers that were completely outside their sphere. The argument, of course, is if one can write and transmit a thought with the clear intent in a way that's rigorous and logical, that any reasonably bright person with reasonable scientific background should be able to understand it. And often these folks with very different scientific backgrounds have perspectives that very clearly improved the paper when they were acted upon. That's a process that doesn't exist in many other journals, I have to say. And I would encourage Joe, which I know, well, he's doing this because he enjoys it and he recognizes its importance, and Joe's successors continue to do that as well because that will ensure the value of the journal through all of the challenges that it is going to have to face in the next decade or two. Dr Amit Khera: I think that was a great point. We're certainly seeing candy bowl examples of the importance of this rigorous process of the editors looking through it carefully and, as you both mentioned, peer review. Joe Hill, I'm going to let you maybe have the last word. I know how hard the three of you have historically worked on your craft for the journal, how much effort you've put in, but I also know it's quite a rewarding job. What would you see as the best part of being Editor-in-Chief of Circulation? Dr Joseph Hill: Oh my, I'm learning something every day. I've been on about a steep a learning curve as when I was an intern at Dr Loscalzo's hospital long ago. Under Dr Willerson's term, I imagine many, many studies came in on acute coronary syndromes and thrombolytic therapy, primary PCI, antiarrhythmic drugs. We haven't seen an antiarrhythmic drug paper except for a recent review we did, but for quite a long time. It's artificial intelligence, it's big data, it's the UK Biobank, it's Omix, it's incredibly sophisticated genetics and genomics and basic science with genetic manipulations, IPS cells. It's a very different world now than it was 10 years ago, 20 years ago and it certainly will be again, 10 and 20 years down the road. We are now approaching, I will say, 600 COVID related papers, and they're still coming in at a record pace. The world has changed. As I said before, this is the 70th anniversary of this storied journal. And it is truly my honor to be able to stand on the shoulders of Doctors Loscalzo and Willerson. Dr Amit Khera: Thank you. I think that's a great way to end this podcast and congratulations on the 70th anniversary. It truly has been a privilege to chat with the three of you today. I want to thank you not only for what you've done for Circulation, but for the field of cardiovascular medicine. This is Amit Khera, digital strategies editor for Circulation. Next week we're back to our usual podcast with Carolyn Lam and Greg Hundley. Take care. Dr Greg Hundley: This program is copyright the American Heart Association, 2020.  

Rookie offensive lineman Lachavious "Pig" Simmons and head strength and conditioning coach Jason Loscalzo join hosts Jeff Joniak, Tom Thayer and Jim Miller on Bears All Access.

Jeff Joniak sits down with head coach Matt Nagy and head strength and conditioning coach Jason Loscalzo on the Bears Coaches Show Podcast.

Podcast: Raider-Cop Podcast Nation Date: Aug 14, 2019 Episode#100 Subject: Tampa Mob Host: Alpha Mike Characters: All American Citizens, Tampa Citizens, LCN Mafia, Cuba  Leadership Quote: "It is when people forget God that tyrants forge their chains." Patrick Henry  Intro: Host Alpha Mike welcomes the audience and reminder us on how to contact us via social network and our website: www.raidercopnation.com Additionally  this episode Tampa Mob will open doors in the #WiseGuySeries with the Cuban Mafia, and many more mafia episodes. Main Topic: Alpha takes us in a historical journey with the Tampa Mafia. How it started, where it went, and what ended up happening. Alpha explains.  What's Next: Cuban Mafia #101 & Cuban Mafia part 2 #102.  Reference: Trafficante Crime Family  Building the Tampa Mob Investigative material for Santo Trafficante  Why mob bigs who met to crown a king had to run like roaches Santo Trafficante Sr  Santos Trafficante Jr Henry Trafficante  Vincent LoScalzo Gambino Family and Tampa  Genovese Family in Florida  Santo Jr in mentorship with Tommy Lucchese  "Santo Jr. started the family's south Florida crew in the early 1980s, he put Steven Bruno Raffa in charge. Bruno ran the crew with associates and freelancers after the death of Santo Jr. Raffa maintained a good relationship with LoScalzo, the new boss of the family and Genovese mobster John Mamone. In 2000 nineteen members of the crew were arrested and Raffa committed suicide." "The Trafficante Family expanded their reach into North Florida cities like Orlando and Jacksonville during the late 1980s. The North Florida operations were run by the Maglianos & Granados. The activities of this crew included money laundering, racketeering, narcotics distribution, and illegal gambling. In May 2015, 13 people in Jacksonville were indicted by the Federal government on money laundering charges." On November 25, 2007, Vincent LoScalzo is now 70 years old a semi-retired mobster and a "regular Joe"said Scott Deitche, author of Cigar City Mafia. The old family membership has died and the Tampa Mob has fallen in the shadows of the NYC mobs. The Only Made Members of the Trafficante Mafia: Salvatore "Sam" Carollo, allegedly became a soldier in the Tampa crime family in the 1980s, he was reportedly brought into the family by Vincent LoScalzo. His legitimate activities include that of a property developer in Pasco County, Florida. @RaiderCopNation @alphamike2017 #RaiderCopNation #AmericasFew @o9TacticalG www.o9tg.com @TestEvery1521 Test Everything 5 minutes on the Power of God  Instagram @raidercoppodcast Parler: @RaiderCopNation Facebook  Twitter iTunes  Spotify   Stitcher  Google Play  PodBean  YouTube TuneIn Join the Raider-Cop NATION Pistol Pete the Gunsmith  Kilo Sierra’s companies: Sepulveda inc #EmpanadaLadiesOfGeorgia #JailsLASD #CACorrections #MDCR #NYPD #LAPD #LASD #MDPD #MPD #NYSP #NJSP #LVPD #Security #HCSO #PBSO #BSO #OCSO #PCSO #SFPD #DPD #HPD #SAPD #LCSO #FMPD #CCSO #NYC #NYCDOC #NJDOC #PPD #SLPD #CPD #TestEverything @RaiderCopNation #RaiderCopNation #TrainUp #o9TG #WiseGuySeries #TrainUpSeries #RollCallSeries #ThinkOuttaDaBox #SideBarSeries

Jason Loscalzo, Head Strength and Conditioning Coach for the Chicago Bears National Football League (NFL) team, talks to the NSCA Head Strength and Conditioning Coach, Scott Caulfield, about his journey from a college to NFL strength and conditioning coach. Topics under discussion include networking, diversifying your portfolio, and coaching philosophy. Find Jason Loscalzo on Twitter: @jason_loscalzo| Find Scott on Instagram: @coachcaulfieldShow Notes“Because as a coach, you always have to think about your future, and you’ve got to be prepared. Because you never know in this business.” 3:00 “If you’re comfortable as a coach, you’re in some bad waters. That’s when I think you start getting complacent and things.” 3:32 “A squat is a squat. A clean is a clean. A snatch is a snatch. But it’s the delivery. It’s how you program it.” 4:18 “That was the biggest thing—the challenge, for me, of figuring out how to do it differently while doing the same thing, getting the same types of results.” 5:01 “But you buckle down, and you go to work. And you do it. You surround yourself with good people.” 18:18 “Give back, give back, give back. I think giving back is just being a good guy. Just be a good person.” 19:29 “We’re strength coaches, and we need to be diversified. And we need to figure out different ways to do things, and to reach different populations.” 21:06 “Coaching is something that’s personal. It’s a relationship. It’s how do you get people to do what you want them to do? How do you make them click? How do you make them tick? How do you make them buy in?” 22:00 “Just be you. Just be who you are. Don’t try and be something fake.” 36:42 “But at the same time, they need to know that you’re there for them. They need to know that you’re there to help them and their career.” 38:32 “They can give me a call, or drop me an email. Any time.” 39:57

Blood sugar imbalances can be hard to spot. And it might surprise you to learn that well-balanced blood sugar is important for maintaining healthy skin. My guest today is Dr. Ritamarie Loscalzo, licensed Doctor of Chiropractic with Certifications in Acupuncture, Nutrition, Herbal Medicine, and HeartMath®.   As the founder of the Institute of Nutritional Endocrinology, Dr. Ritamarie specializes in using the wisdom of nature to restore balance to hormones with a special emphasis on thyroid, adrenal, and insulin imbalances. She has trained and certified hundreds of practitioners in the art of using palate-pleasing whole fresh food as medicine. Best-selling author, speaker, and internationally recognized nutrition and women's health authority with over 25 years of clinical experience, Dr. Ritamarie offers online courses, long-distance coaching, counseling, and informative live events. Join us as we talk about all things blood sugar: why it's important, how it affects the skin, and how to balance it. Has your skin condition improved after balancing blood sugar? Tell me about it in the comments!   In this episode: Why should you care if your blood sugar is not well balanced? More effective ways than the fasting glucose marker to tell whether your blood sugar is imbalanced What if a fasting blood sugar level is all you have? Can stress impact your blood sugar? Symptoms of possible blood sugar imbalance Why is what we eat important?   Quotes "Blood sugar regulation is important because every cell in the body needs to get a source of energy, a source of fuel, in order to do its thing. So in order for skin cells to be able to reproduce properly and get the right nutrition in, there needs to be a balance in blood sugar and the escort hormone (called insulin)." [3:06] "When insulin resistance starts, we get a lack of nourishment to all of our cells. Skin included." [5:00] "The mechanism is: when we perceive stress, our blood sugar goes up, our cortisol goes up. Because that's what the adrenals do. They produce cortisol. And one of cortisol's jobs is to raise the blood sugar and the blood pressure and the heart rate and the respiration rate." [11:28]   Links Find Dr. Ritamarie online FREE CHECKLIST: Foods that reverse belly fat, fatigue, and lack of focus Dr. Ritamarie's book, Unstoppable Health: 7 Breakthrough Habits to Feel Younger, Grow Stronger, And Enjoy More Energy Follow Dr. Ritamarie on Facebook | Twitter How to Make a Protein Shake List of Labs For Your Skin To Ask Your Doctor About

Ritamarie, the author of “Unstoppable Health” is a licensed Doctor of Chiropractic with Certification in Acupuncture, a Diplomat of the American Clinical Nutrition Board and founder of the Institute of Nutritional Endocrinology. She is a Certified Clinical Nutritionist with a Master’s degree in Human Nutrition, and has completed a 500-hour Herbal Medicine Certification Program. She founded the Institute of Nutritional Endocrinology so that she could be instrumental in transforming our current broken disease-management system into a true health care system where every practitioner is skilled at finding the root cause of health challenges.

Ritamarie, the author of “Unstoppable Health” is a licensed Doctor of Chiropractic with Certification in Acupuncture, a Diplomat of the American Clinical Nutrition Board and founder of the Institute of Nutritional Endocrinology. She is a Certified Clinical Nutritionist with a Master’s degree in Human Nutrition, and has completed a 500-hour Herbal Medicine Certification Program. She founded the Institute of Nutritional Endocrinology so that she could be instrumental in transforming our current broken disease-management system into a true health care system where every practitioner is skilled at finding the root cause of health challenges.

  Watch the full interview below or listen to the full episode on your iPhone HERE. Stu: This week we welcome Dr. Ritamarie Loscalzo to the show. Dr. Ritamarie Loscalzo is fiercely committed to transforming our current broken disease-care system into a true health care system where each and every practitioner is skilled at finding the root cause of health challenges and using ancient healing wisdom married with modern scientific research to restore balance. As the founder of the Institute of Nutritional Endocrinology, Dr. Ritamarie specializes in using the wisdom of nature to restore balance to hormones with a special emphasis on thyroid, adrenal, and insulin imbalances. Her practitioner training programs empower health and nutrition practitioners to get to the root cause of health concerns by using functional assessments and natural therapeutics to balance the endocrine system, the master controller. Dr. Ritamarie is a licensed Doctor of Chiropractic with Certification in Acupuncture and is a Diplomat of the American Clinical Nutrition Board. She is a Certified Clinical Nutritionist with a Master of Science in Human Nutrition and Computer Science, and she has completed a 2-year, 500-hour Herbal Medicine Program. Dr. Ritamarie is also a certified living foods chef, instructor, and coach, and she has trained and certified hundreds of others in the art of using palate-pleasing, whole fresh food as medicine. As a certified HeartMath® provider, Dr. Ritamarie is passionate about using HeartMath® techniques to guide clients and reduce the negative impact of stress on their health. A best-selling author, speaker, and internationally recognized nutrition and women’s health authority with over 23 years of clinical experience, Dr. Ritamarie offers online courses, long-distance coaching and counseling, and deeply empowering and informative live events. Her articles have appeared in the Journal of Nutritional Perspectives, Natural Awakenings, Purely Delicious, and many other national magazines as well as countless online publications. Questions we ask in this episode: What techniques can we consider to reduce stress in our everyday lives? What causes brain fog and how can we reduce it? Can you explain the principles behind HeartMath® https://shop.180nutrition.com.au/ Stu 00:44 This week I'm excited to welcome Dr. Ritamarie Loscalzo. Dr. Ritamarie has a chiropractor, nutritionist, and nutritional endocrinology specialists. She educates those who want to understand and attack the root cause of their health issues to resolve, rather than take pills or trendy diets to mask the problem. In this episode, we discuss the issues of stress from feeling tired and wired to the tools, tips, and strategies to eliminate brain fog and boost energy. Dr. Ritamarie also shares a 2-minute breathing tip that can really change your day. Anyway enough from me, let's get into the show. 01:25 Hey guys, this is Stu from 180 Nutrition and I am delighted to welcome Dr. Ritamarie Loscalzo to the show today. Good morning Dr. Ritamarie, how are you? Ritamarie 01:25 Good afternoon. Stu 01:35 Good afternoon. I've said that every single time in different parts of the world. Loving the backdrop as well. I have to say for everybody that's listening or watching us on video version, yeah, it's definitely where we want to be today. First up, for everybody out there that may not be familiar with your work, I would love it if you could just tell us a little bit about yourself, what you do and perhaps why you do it. Ritamarie 02:04 Yeah, absolutely. I am passionate about helping people to regain their energy, their vitality, and to be the best of themselves so that they can live the life they were intended. I so often see people struggling and suffering and saddling basically for not really living the life that they want to because they're exhausted, their brain fogged, they'd just feel out of balance and out of sorts. I also am so passionate about changing the way the system works because I think a lot of it is because we're brainwashed from the time we're little that you have an ache or pain, you go to the doctor, you get a pill, and it takes care of it. As you age, you get frail and slow down and all that kind of stuff, and we expect that so we get it. 02:51 I think that our system needs to change. I also train health practitioners in the art of using nutrition to affect endocrinology and, use holistic and functional medicine techniques, and to do that in a big part is empowering people. It's what I call self-empowered healthcare. Why am I so passionate about that is I lost my own health when I was in my 20s when time of your life when you think you're at your peak. I was able to regain it, not through Western medicine, but through the kind of work that I now do, which is in nutrition and functional medicine. 03:24 I also lost three very close to actually more than three, but three extremely close family members; my mother, my father, and my sister to what I think were preventable illnesses, but their doctors didn't know what to tell them to do to change their diet and lifestyle. For full transcript and interview: http://180nutrition.com.au/180-tv/dr-ritamarie-l…alzo-interview/  

Fotografia e música. É assim que se divide a vida do menino Stefano Loscalzo. Um menino preso em um corpo de um bebê gigante de 2 metros que foi criado pescando nas águas da cidade interiorana em que nasceu, e que ele mesmo insiste em afirmar que foi a cidade que enviou a "primeira água que foi pra lua". Nesse podcast ele dá várias dicas legais pra galera que tá começando na fotografia. Desde lentes, câmeras até alguns macetes pra deixar a/o modelo mais a vontade na hora da foto. 

AAIM Interviews J Loscalzo Chair BWH by Mountainlion

Dr. Ritamarie Loscalzo is a licensed Doctor of Chiropractic with Certification in Acupuncture and is a Diplomat of the American Clinical Nutrition Board. In this show we talk about blood sugar and why it's important to balance it for hormone health, prevent weight gain, prevent diabetes and heart disease, among others. We carry the supplements mentioned in this episode through our online store. Please see the resources section below for the list of supplements. If you've never shopped with us, you can take 20% off your first order with the coupon code FIRST20. You will need to create an account / log in to be able to apply the promo code. Shipping is always free!  Our store: http://womenswellness.ehealthpro.com Here's what you'll hear: Min 03:15 Introduction to Dr. Ritamarie Loscalzo Min 04:15 Why balancing blood sugar is important Min 10:40 Eating healthy Min 15:05 Techniques to lower blood sugar Min 17:20 Gut health & stress Min 18:45 Testing blood sugar Min 27:00 Blood sugar levels Min 31:20 Balancing blood sugar Min 37:40 Plant/Vegetable centred diets Min 43:50 Blood sugar & female hormones Min 48:20 Dr. Loscalzo's program To learn more about Dr. Ritamarie Loscalzo, visit her website here and follow her on social media: Facebook Twitter Instagram YouTube Google+ Resources: OmegAvail™ Ultra DHA 60 softgels Magnesium Chelate Powder 150 g (5.3 oz) Chromium Synergy™ 90 vegetarian capsules The Sweet Spot program Insulin Resistance Solution Practitioner Training (IRSPT) Scientific and Holistic Investigation of Nutritional Endocrinology (SHINE) Conference

Healthy living heroine and juice cleansing guru, Ritamarie Loscalzo joins us for a conversation about how, why, when and what to do in order to successfully juice cleanse. There's a fair amount of controversy on whether or not it's safe to do a short juice cleanse, and this interview dives in deep to discuss the details. You'll love Ritamarie's warm nature and comprehensive knowledge of detox. Having worked with her for many years, and hundreds of hours, she's a woman of integrity who takes her patient's well-being to heart. Dive in and discover why juice cleansing might just be the perfect next step for you, too! You can learn more about Dr. Ritamarie here: http://www.drritamarie.com/    

Many people don't know they are walking around with elevated blood sugar - and that can put you at risk for dementia, peripheral neuropathy and all sorts of bad news. In this episode you will hear from chiropractor and nutritionist Dr. Ritamarie Loscalzo on how to use blood sugar monitoring to design a lifestyle perfect for you so you can create the health you want. When you balance your blood sugar you fix a lot of things FAST and what you're about to learn is going to help you recharge your energy and reclaim your life!

A review of Osteoarthritis  for the the Pain Practitioner. To hear about Ankylosing spondylitis please subscribe to our premium episodes Discussed: Joint Replacement DMARDs NSAIDs Syndesmophytes Crepitus Xray findings Bouchards PainExam Podcast Download our iphone App! Download our Android App! For more information on Pain Management Topics and keywords Go to PainExam.com David Rosenblum, MD specializes in Pain Management and is the Director of Pain Management at Maimonides Medical Center and AABP Pain Managment For evaluation and treatment of a Painful Disorder, go to www.AABPPain.com 718 436 7246 DISCLAIMER: Doctor Rosenblum IS HERE SOLELY TO EDUCATE, AND YOU ARE SOLELY RESPONSIBLE FOR ALL YOUR DECISIONS AND ACTIONS IN RESPONSE TO ANY INFORMATION CONTAINED HEREIN. This podcasts is not intended as a substitute for the medical advice of physician to a particular patient or specific ailment.  You should regularly consult a physician in matters relating to yours or another's health.  You understand that this podcast is not intended as a substitute for consultation with a licensed medical professional.  Copyright © 2015 QBazaar.com, LLC  All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, recording or otherwise, without the prior written permission of the author. References https://en.wikipedia.org/wiki/Ankylosing_spondylitis https://en.wikipedia.org/wiki/Osteoarthritis "Ankylosing Spondylitis -Professional reference for Doctors - Patient UK". Patient UK. Retrieved 26 May 2014. Jump up ^ Jiménez-Balderas FJ, Mintz G (1993). "Ankylosing spondylitis: clinical course in women and men". J Rheumatol 20 (12): 2069–72. PMID 7516975. Jump up ^ Longo, Dan Louis; Fauci, Anthony S.; Harrison, Tinsley Randolph; Kasper, Dennis L.; Hauser, Stephen L.; Jameson, J. Larry; Loscalzo, Joseph (2012). Harrison's Principles of Internal Medicine. Vol. 1 (18th ed.). McGraw-Hill. ISBN 978-0-07-163244-7. Jump up ^ "Ankolysing Spondylitis". Arthritis Action. Retrieved 12 August 2015. Jump up ^ Thomas E, Silman AJ, Papageorgiou AC, Macfarlane GJ, Croft PR (1998). "Association between measures of spinal mobility and low back pain. An analysis of new attenders in primary care". Spine 23 (2): 343–7. doi:10.1097/00007632-199802010-00011. PMID 9507623. Jump up ^ Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994). "A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index". J Rheumatol 21 (12): 2286–91. PMID 7699630. Jump up ^ Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T (1994). "A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index". J Rheumatol 21 (12): 2281–5. PMID 7699629. Jump up ^ Toivanen A, Möttönen T (1998). "Ankylosing spondylitis: current approaches to treatment". BioDrugs 10 (3): 193–200. doi:10.2165/00063030-199810030-00003. PMID 18020595. Jump up ^ Williams RO, Paleolog E, Feldmann M (2007). "Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases". Curr Opin Pharmacol 7 (4): 412–7. doi:10.1016/j.coph.2007.06.001. PMID 17627887. Jump up ^ Kroon F, Landewé R, Dougados M, van der Heijde D (October 2012). "Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis". Ann. Rheum. Dis. 71 (10): 1623–9. doi:10.1136/annrheumdis-2012-201370. PMID 22532639. Jump up ^ Chen J, Lin S, Liu C (27 November 2014). "Sulfasalazine for ankylosing spondylitis.". The Cochrane database of systematic reviews 11: CD004800. doi:10.1002/14651858.CD004800.pub3. PMID 25427435. Jump up ^ Chen J, Veras MM, Liu C, Lin J (28 February 2013). "Methotrexate for ankylosing spondylitis.". The Cochrane database of systematic reviews 2: CD004524. doi:10.1002/14651858.CD004524.pub4. PMID 23450553. Jump up ^ Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D (June 2011). "2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis". Ann. Rheum. Dis. 70 (6): 896–904. doi:10.1136/ard.2011.151027. PMC 3086052. PMID 21540199. Jump up ^ Braun J, Sieper J (2007). "Ankylosing spondylitis". Lancet 369 (9570): 1379–90. doi:10.1016/S0140-6736(07)60635-7. PMID 17448825. Jump up ^ Brulhart L, Nissen MJ, Chevallier P, Gabay C (February 2010). "Mixed response to tocilizumab for ankylosing spondylitis". Annals of the Rheumatic Diseases 69 (12): 2217–2218. doi:10.1136/ard.2009.126706. PMID 20851032. Jump up ^ Rodríguez-Escalera C, Fernández-Nebro A (2008). "The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B". Rheumatology47 (11): 1732–1733. doi:10.1093/rheumatology/ken362. PMID 18786966. Jump up ^ "Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions: overview and methodology". Phys Ther 81 (10): 1629–40. 2001. PMID 11589641. Jump up ^ Dagfinrud H, Kvien TK, Hagen KB (23 January 2008). "Physiotherapy interventions for ankylosing spondylitis.". The Cochrane database of systematic reviews (1): CD002822. doi:10.1002/14651858.CD002822.pub3. PMID 18254008. Jump up ^ Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002). "Ankylosing spondylitis: an overview". Ann. Rheum. Dis. 61 Suppl 3: iii8–18. doi:10.1136/ard.61.suppl_3.iii8. PMC 1766729. PMID 12381506. Jump up ^ Bond D (2013). "Ankylosing spondylitis: diagnosis and management". Nurs Stand 28 (16-18): 52–9; quiz 60. doi:10.7748/ns2013.12.28.16.52.e7807. PMID 24345154. ^ Jump up to: a b Alpert, Joseph S. (2006). The AHA Clinical Cardiac Consult. Lippincott Williams & Wilkins. ISBN 0-7817-6490-4. Jump up ^ Ahn NU, Ahn UM, Nallamshetty L, Springer BD, Buchowski JM, Funches L, Garrett ES, Kostuik JP, Kebaish KM, Sponseller PD (2001). "Cauda Equina Syndrome in AS (The CES-AS Syndrome): Meta-analysis of outcomes after medical and surgical treatments". J of Spinal Disorders 14 (5): 427–433. doi:10.1097/00002517-200110000-00009. PMID 11586143. ^ Jump up to: a b Bakland G, Gran JT, Nossent JC (November 2011). "Increased mortality in ankylosing spondylitis is related to disease activity". Ann. Rheum. Dis.70 (11): 1921–5. doi:10.1136/ard.2011.151191. PMID 21784726. Jump up ^ Radford EP, Doll R, Smith PG (September 1977). "Mortality among patients with ankylosing spondylitis not given X-ray therapy". N. Engl. J. Med. 297(11): 572–6. doi:10.1056/NEJM197709152971103. PMID 887115. Jump up ^ Del Din S, Carraro E, Sawacha Z, Guiotto A, Bonaldo L, Masiero S, Cobelli C (2011). "Impaired gait in ankylosing spondylitis". Med Biol Eng Comput 49(7): 801–9. doi:10.1007/s11517-010-0731-x. PMID 21229328 "Ankylosing Spondylitis -Professional reference for Doctors - Patient UK". Patient UK. Retrieved 26 May 2014. 2.Jump up ^ Jiménez-Balderas FJ, Mintz G (1993). "Ankylosing spondylitis: clinical course in women and men". J Rheumatol 20 (12): 2069–72. PMID 7516975. 3.Jump up ^ Longo, Dan Louis; Fauci, Anthony S.; Harrison, Tinsley Randolph; Kasper, Dennis L.; Hauser, Stephen L.; Jameson, J. Larry; Loscalzo, Joseph (2012). Harrison's Principles of Internal Medicine. Vol. 1 (18th ed.). McGraw-Hill. ISBN 978-0-07-163244-7. 4.Jump up ^ "Ankolysing Spondylitis". Arthritis Action. Retrieved 12 August 2015. 5.Jump up ^ Thomas E, Silman AJ, Papageorgiou AC, Macfarlane GJ, Croft PR (1998). "Association between measures of spinal mobility and low back pain. An analysis of new attenders in primary care". Spine 23 (2): 343–7. doi:10.1097/00007632-199802010-00011. PMID 9507623. 6.Jump up ^ Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994). "A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index". J Rheumatol 21 (12): 2286–91. PMID 7699630. 7.Jump up ^ Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T (1994). "A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index". J Rheumatol 21 (12): 2281–5. PMID 7699629. 8.Jump up ^ Toivanen A, Möttönen T (1998). "Ankylosing spondylitis: current approaches to treatment". BioDrugs 10 (3): 193–200. doi:10.2165/00063030-199810030-00003. PMID 18020595. 9.Jump up ^ Williams RO, Paleolog E, Feldmann M (2007). "Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases". Curr Opin Pharmacol 7 (4): 412–7. doi:10.1016/j.coph.2007.06.001. PMID 17627887. 10.Jump up ^ Kroon F, Landewé R, Dougados M, van der Heijde D (October 2012). "Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis". Ann. Rheum. Dis. 71 (10): 1623–9. doi:10.1136/annrheumdis-2012-201370. PMID 22532639. 11.Jump up ^ Chen J, Lin S, Liu C (27 November 2014). "Sulfasalazine for ankylosing spondylitis.". The Cochrane database of systematic reviews 11: CD004800. doi:10.1002/14651858.CD004800.pub3. PMID 25427435. 12.Jump up ^ Chen J, Veras MM, Liu C, Lin J (28 February 2013). "Methotrexate for ankylosing spondylitis.". The Cochrane database of systematic reviews 2: CD004524. doi:10.1002/14651858.CD004524.pub4. PMID 23450553. 13.Jump up ^ Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D (June 2011). "2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis". Ann. Rheum. Dis. 70 (6): 896–904. doi:10.1136/ard.2011.151027. PMC 3086052. PMID 21540199. 14.Jump up ^ Braun J, Sieper J (2007). "Ankylosing spondylitis". Lancet 369 (9570): 1379–90. doi:10.1016/S0140-6736(07)60635-7. PMID 17448825. 15.Jump up ^ Brulhart L, Nissen MJ, Chevallier P, Gabay C (February 2010). "Mixed response to tocilizumab for ankylosing spondylitis". Annals of the Rheumatic Diseases 69 (12): 2217–2218. doi:10.1136/ard.2009.126706. PMID 20851032. 16.Jump up ^ Rodríguez-Escalera C, Fernández-Nebro A (2008). "The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B". Rheumatology 47 (11): 1732–1733. doi:10.1093/rheumatology/ken362. PMID 18786966. 17.Jump up ^ "Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions: overview and methodology". Phys Ther 81 (10): 1629–40. 2001. PMID 11589641. 18.Jump up ^ Dagfinrud H, Kvien TK, Hagen KB (23 January 2008). "Physiotherapy interventions for ankylosing spondylitis.". The Cochrane database of systematic reviews (1): CD002822. doi:10.1002/14651858.CD002822.pub3. PMID 18254008. 19.Jump up ^ Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002). "Ankylosing spondylitis: an overview". Ann. Rheum. Dis. 61 Suppl 3: iii8–18. doi:10.1136/ard.61.suppl_3.iii8. PMC 1766729. PMID 12381506. 20.Jump up ^ Bond D (2013). "Ankylosing spondylitis: diagnosis and management". Nurs Stand 28 (16-18): 52–9; quiz 60. doi:10.7748/ns2013.12.28.16.52.e7807. PMID 24345154. 21.^ Jump up to: a b Alpert, Joseph S. (2006). The AHA Clinical Cardiac Consult. Lippincott Williams & Wilkins. ISBN 0-7817-6490-4. 22.Jump up ^ Ahn NU, Ahn UM, Nallamshetty L, Springer BD, Buchowski JM, Funches L, Garrett ES, Kostuik JP, Kebaish KM, Sponseller PD (2001). "Cauda Equina Syndrome in AS (The CES-AS Syndrome): Meta-analysis of outcomes after medical and surgical treatments". J of Spinal Disorders 14 (5): 427–433. doi:10.1097/00002517-200110000-00009. PMID 11586143. 23.^ Jump up to: a b Bakland G, Gran JT, Nossent JC (November 2011). "Increased mortality in ankylosing spondylitis is related to disease activity". Ann. Rheum. Dis. 70 (11): 1921–5. doi:10.1136/ard.2011.151191. PMID 21784726. 24.Jump up ^ Radford EP, Doll R, Smith PG (September 1977). "Mortality among patients with ankylosing spondylitis not given X-ray therapy". N. Engl. J. Med. 297 (11): 572–6. doi:10.1056/NEJM197709152971103. PMID 887115. 25.Jump up ^ Del Din S, Carraro E, Sawacha Z, Guiotto A, Bonaldo L, Masiero S, Cobelli C (2011). "Impaired gait in ankylosing spondylitis". Med Biol Eng Comput 49 (7): 801–9. doi:10.1007/s11517-010-0731-x. PMID 21229328 ^ Jump up to: a b c d e f g h i "Osteoarthritis". National Institute of Arthritis and Musculoskeletal and Skin Diseases. April 2015. Retrieved 13 May 2015. ^ Jump up to: a b c d Glyn-Jones, S; Palmer, AJ; Agricola, R; Price, AJ; Vincent, TL; Weinans, H; Carr, AJ (3 March 2015). "Osteoarthritis.". Lancet. PMID 25748615. Jump up ^ Berenbaum F (2013). "Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!)". Osteoarthritis and Cartilage 21 (1): 16–21. doi:10.1016/j.joca.2012.11.012. PMID 23194896. ^ Jump up to: a b Conaghan P (2008). "Osteoarthritis — National clinical guideline for care and management in adults" (PDF). ^ Jump up to: a b March, L; Smith, EU; Hoy, DG; Cross, MJ; Sanchez-Riera, L; Blyth, F; Buchbinder, R; Vos, T; Woolf, AD (June 2014). "Burden of disability due to musculoskeletal (MSK) disorders.". Best practice & research. Clinical rheumatology 28 (3): 353–66. PMID 25481420. Jump up ^ Elsternwick (2013). "A problem worth solving.". Arthritis and Osteoporosis Victoria. Jump up ^ MedlinePlus Encyclopedia Osteoarthritis Jump up ^ de Figueiredo EC, Figueiredo GC, Dantas RT (December 2011). "Influência de elementos meteorológicos na dor de pacientes com osteoartrite: Revisão da literatura" [Influence of meteorological elements on osteoarthritis pain: a review of the literature]. Rev Bras Reumatol (in Portuguese) 51 (6): 622–8. doi:10.1590/S0482-50042011000600008. PMID 22124595. Jump up ^ "Water on the knee". MayoClinic.com. ^ Jump up to: a b Brandt KD, Dieppe P, Radin E (January 2009). "Etiopathogenesis of osteoarthritis". Med. Clin. North Am. 93 (1): 1–24, xv. doi:10.1016/j.mcna.2008.08.009. PMID 19059018. Jump up ^ Bosomworth NJ (September 2009). "Exercise and knee osteoarthritis: benefit or hazard?". Can Fam Physician 55 (9): 871–8. PMC 2743580. PMID 19752252. Jump up ^ Deweber K, Olszewski M, Ortolano R (2011). "Knuckle cracking and hand osteoarthritis". J Am Board Fam Med 24 (2): 169–74. doi:10.3122/jabfm.2011.02.100156. PMID 21383216. Jump up ^ Valdes AM, Spector TD (August 2008). "The contribution of genes to osteoarthritis". Rheum. Dis. Clin. North Am. 34 (3): 581–603. doi:10.1016/j.rdc.2008.04.008. PMID 18687274. Jump up ^ Spector TD, MacGregor AJ (2004). "Risk factors for osteoarthritis: genetics". Osteoarthr. Cartil. 12 Suppl A: S39–44. doi:10.1016/j.joca.2003.09.005. PMID 14698640. Jump up ^ Hogervorst T, Bouma HW, de Vos J (August 2009). "Evolution of the hip and pelvis.". Acta orthopaedica. Supplementum 80 (336): 1–39. doi:10.1080/17453690610046620. PMID 19919389. Jump up ^ van der Kraan PM, van den Berg WB (April 2008). "Osteoarthritis in the context of ageing and evolution. Loss of chondrocyte differentiation block during ageing.". Ageing Research Reviews 7 (2): 106–13. doi:10.1016/j.arr.2007.10.001. PMID 18054526. Jump up ^ Coggon D, Reading I, Croft P, McLaren M, Barrett D, Cooper C (May 2001). "Knee osteoarthritis and obesity". Int. J. Obes. Relat. Metab. Disord. 25 (5): 622–7. doi:10.1038/sj.ijo.0801585. PMID 11360143. Jump up ^ Pottie P, Presle N, Terlain B, Netter P, Mainard D, Berenbaum F (November 2006). "Obesity and osteoarthritis: more complex than predicted!". Ann. Rheum. Dis. 65 (11): 1403–5. doi:10.1136/ard.2006.061994. PMC 1798356. PMID 17038451. Jump up ^ Linn S, Murtaugh B, Casey E (May 2012). "Role of sex hormones in the development of osteoarthritis". PM R 4 (5 Suppl): S169–73. doi:10.1016/j.pmrj.2012.01.013. PMID 22632696. Jump up ^ Tanamas SK, Wijethilake P, Wluka AE, Davies-Tuck ML, Urquhart DM, Wang Y, Cicuttini FM (June 2011). "Sex hormones and structural changes in osteoarthritis: a systematic review". Maturitas 69 (2): 141–56. doi:10.1016/j.maturitas.2011.03.019. PMID 21481553. Jump up ^ Ma HL, Blanchet TJ, Peluso D, Hopkins B, Morris EA, Glasson SS (June 2007). "Osteoarthritis severity is sex dependent in a surgical mouse model". Osteoarthr. Cartil. 15 (6): 695–700. doi:10.1016/j.joca.2006.11.005. PMID 17207643. Jump up ^ King KB, Rosenthal AK (2015). "The adverse effects of diabetes on osteoarthritis: update on clinical evidence and molecular mechanisms". Osteoarthritis Cartilage 23 (6): 841–50. doi:10.1016/j.joca.2015.03.031. PMID 25837996. ^ Jump up to: a b c Maroudas AI (April 1976). "Balance between swelling pressure and collagen tension in normal and degenerate cartilage". Nature 260 (5554): 808–9. doi:10.1038/260808a0. PMID 1264261. Jump up ^ Bollet AJ, Nance JL (July 1966). "Biochemical Findings in Normal and Osteoarthritic Articular Cartilage. II. Chondroitin Sulfate Concentration and Chain Length, Water, and Ash Content". J. Clin. Invest. 45 (7): 1170–7. doi:10.1172/JCI105423. PMC 292789. PMID 16695915. ^ Jump up to: a b Brocklehurst R, Bayliss MT, Maroudas A, Coysh HL, Freeman MA, Revell PA, Ali SY (January 1984). "The composition of normal and osteoarthritic articular cartilage from human knee joints. With special reference to unicompartmental replacement and osteotomy of the knee". J Bone Joint Surg Am 66 (1): 95–106. PMID 6690447. Jump up ^ Chou MC, Tsai PH, Huang GS, Lee HS, Lee CH, Lin MH, Lin CY, Chung HW (April 2009). "Correlation between the MR T2 value at 4.7 T and relative water content in articular cartilage in experimental osteoarthritis induced by ACL transection". Osteoarthr. Cartil. 17 (4): 441–7. doi:10.1016/j.joca.2008.09.009. PMID 18990590. Jump up ^ Grushko G, Schneiderman R, Maroudas A (1989). "Some biochemical and biophysical parameters for the study of the pathogenesis of osteoarthritis: a comparison between the processes of ageing and degeneration in human hip cartilage". Connect. Tissue Res. 19 (2–4): 149–76. doi:10.3109/03008208909043895. PMID 2805680. Jump up ^ Mankin HJ, Thrasher AZ (January 1975). "Water content and binding in normal and osteoarthritic human cartilage". J Bone Joint Surg Am 57 (1): 76–80. PMID 1123375. ^ Jump up to: a b Venn M, Maroudas A (April 1977). "Chemical composition and swelling of normal and osteoarthrotic femoral head cartilage. I. Chemical composition". Ann. Rheum. Dis. 36 (2): 121–9. doi:10.1136/ard.36.2.121. PMC 1006646. PMID 856064. Jump up ^ Madry H, Luyten FP, Facchini A (2012). "Biological aspects of early osteoarthritis". Knee Surg. Sports Traumatol. Arthrosc. 20 (3): 407–22. doi:10.1007/s00167-011-1705-8. PMID 22009557. Jump up ^ Englund M, Roemer FW, Hayashi D, Crema MD, Guermazi A (2012). "Meniscus pathology, osteoarthritis and the treatment controversy". Nat. Rev. Rheumatol. 8 (7): 412–9. doi:10.1038/nrrheum.2012.69. PMID 22614907. Jump up ^ Li G, Yin J, Gao J, Cheng TS, Pavlos NJ, Zhang C, Zheng MH (2013). "Subchondral bone in osteoarthritis: insight into risk factors and microstructural changes". Arthritis Res. Ther. 15 (6): 223. doi:10.1186/ar4405. PMID 24321104. Jump up ^ Hill CL, Gale DG, Chaisson CE, Skinner K, Kazis L, Gale ME, Felson DT (2001). "Knee effusions, popliteal cysts, and synovial thickening: association with knee pain in osteoarthritis". J. Rheumatol. 28 (6): 1330–7. PMID 11409127. Jump up ^ Felson DT, Chaisson CE, Hill CL, Totterman SM, Gale ME, Skinner KM, Kazis L, Gale DR (2001). "The association of bone marrow lesions with pain in knee osteoarthritis". Ann Intern Med. 2001 Apr 3;134(7):541-9 134 (7): 541–9. doi:10.7326/0003-4819-134-7-200104030-00007. PMID 11281736. Jump up ^ Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B, Herrero-Beaumont G, Kirschner S, Leeb BF, Lohmander LS, Mazières B, Pavelka K, Punzi L, So AK, Tuncer T, Watt I, Bijlsma JW (March 2010). "EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis". Ann. Rheum. Dis. 69 (3): 483–9. doi:10.1136/ard.2009.113100. PMID 19762361. Jump up ^ Bierma-Zeinstra SM, Oster JD, Bernsen RM, Verhaar JA, Ginai AZ, Bohnen AM (August 2002). "Joint space narrowing and relationship with symptoms and signs in adults consulting for hip pain in primary care". J. Rheumatol. 29 (8): 1713–8. PMID 12180735. Jump up ^ Osteoarthritis (OA): Joint Disorders at Merck Manual of Diagnosis and Therapy Professional Edition Jump up ^ Phillips CR, Brasington RD (2010). "Osteoarthritis treatment update: Are NSAIDs still in the picture?". Journal of Musculoskeletal Medicine 27 (2). Jump up ^ Kalunian KC (2013). "Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)". UpToDate. Retrieved 15 February 2013. Jump up ^ Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke TD, Daniel W, Gray R (November 1990). "The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand". Arthritis Rheum. 33 (11): 1601–10. doi:10.1002/art.1780331101. PMID 2242058.

The present work deals with the inhibitory action of ANP on TNF- -induced expression of adhesion molecules (ICAM-1, VCAM-1, E-selectin), chemokines (MCP-1), and cytoskeleton changes in human endothelial cells. 5.1.1 Effect of ANP on TNF- α αα-induced CAM expression The following diagram shows a schematic outdraw of the summerized results of the first part of the present work. figure 1 summary: schematic diagram of the signal transduction pathways clarified by the first section of the present work It has been shown before that TNF- increases the expression of cell adhesion molecules E-selectin and ICAM-1 via activation of the transcription factor NF- B. We could show that ANP is able to inhibit the activation of NF- B via binding its guanylyl-cyclase-coupled NPR-A and -B receptor. We could further elucidate the molecular mechanism leading to the inhibition of NF- B activation by ANP. ANP was shown to transcriptionally activate the expression of I B isoforms. In consequence of the ANP mediated inhibition of NF- B DNA-binding activity we could demonstrate an attenuated surface expression of E-selectin and ICAM-1. E-selectin ICAM-1 NF- κκB κ B 5.1.2 Effect of ANP on TNF- αα α -induced cytoskeleton and perme- ability changes The following figure shows an outdraw of the summerized results of the second part of the present work. figure 2 summary: schematic diagram of the signal transduction pathways clarified by the second section of the present work TNF- has been shown to induce changes in cytoskeleton and macromolecule permeability of endothelial cells. We have shown here for the first time that ANP is able to abrogate both TNF- - induced effects via its guanylyl-cyclase-coupled NPR-A receptor. Moreover, ANP was shown to reduce TNF- -induced F-actin polymerization and stress fiber formation via the inhibition of p38 MAPK and its downstream target HSP27. Furthermore we could report here for the first time a decrease in TNF- -induced macromolecule permeability by ANP. The deactivation of p38 MAPK was demonstrated to be mediated via a significant transcriptional induction of the MKP-1 by ANP. intercellular gap5.1.3 Effect of ANP on TNF- α αα-induced MCP-1 expression The results of the third part of the present work are summerized in figure 3. figure 3 summary: schematic diagram of the signal transduction pathways clarified by the first and third section of the present work It is known that TNF- induces the release of MCP-1 during inflammatory processes via influencing the transcription factor NF- B and the p38 MAPK pathway. We could report here for the first time a decreased TNF- -induced MCP-1 expression by treatment of endothelial cells with ANP. The observed ANP effect was shown to be mediated via the particulate guanylyl-cyclase-coupled NPR. Furthermore we show that trancriptional induction of MKP-1 by ANP is essential for inhibition of TNF- - induced MCP-1 expression by ANP. In summary the data presented here provides evidence that ANP is able to preserve the structure and function of endothelial cells. These observations are of special importance because there is clear evidence that endothelial cell dysfunction is the cause for many acute and chronic vascular diseases (Biegelsen and Loscalzo 1999). The potency of an endogenous compound, i.e. ANP, to protect against such endothelial dysfunction points to an antiinflammatory and antiatherogenic potential of this cardiovascular hormone. This work has been supported by the DFG (Vo376/8-1). macromolecule